Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
204
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Rose Parisia Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-2454-6895View further author information
ORCID Icon,
Emily A. Cowena Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Stephanie Gua Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Stephen Duszaa Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Melissa Pulitzerb Department of Pathology and Laboratory Medicine, Dermatopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Medical College, Cornell University, New York, NY, USAView further author information
,
Mark B. Geyerd Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-5248-9117View further author information
ORCID Icon,
Amber C. Kinge Department of Pharmacy, Clinical Services, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
Alina Markovaa Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Medical College, Cornell University, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2427-3199View further author information
ORCID Icon show all
Pages 1583-1587 | Received 12 Dec 2022, Accepted 24 May 2023, Published online: 12 Jun 2023

References

  • Pulte ED, Vallejo J, Przepiorka D, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23(11):1366–1371. doi: 10.1634/theoncologist.2018-0179
  • Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783
  • Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–1802. doi: 10.1200/JCO.2016.69.3531
  • Goekbuget N, Dombret H, Zugmaier G, et al. Blinatumomab for minimal residual disease (MRD) in adults with B-Cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months. Blood. 2018;132(Suppl. 1):​554. doi: 10.1182/blood-2018-99-111516
  • Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–6233. doi: 10.1182/blood-2012-01-400515
  • Blinatumomab for injection, for intravenous use. Contract no.: 4241595. Thousand Oaks, CA: Food and Drug Administration; 2018
  • Division2021. MSKCCDT. Dataline MED24582; 2023
  • Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–4039. doi: 10.1158/1078-0432.CCR-15-0612
  • Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–298. doi: 10.1093/jjco/hyv207
  • Leporini C, Saullo F, Filippelli G, et al. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: a case review. J Pharmacol Pharmacother. 2013;4(Suppl. 1):S78–S85. doi: 10.4103/0976-500X.120966
  • Robinson HR, Qi J, Cook EM, et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood. 2018;​132(5):521–532. doi: 10.1182/blood-2018-02-830992

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.